Litigation

Recent Posts

6th Circuit Panel Affirms Most Darvon/Darvocet/Propoxyphene Claims Are Preempted
Posted on 30 Jun 2014 by Tom Moylan

CINCINNATI — (Mealey’s) The Sixth Circuit U.S. Court of Appeals on June 27 affirmed dismissal of 67 of 68 Darvon/Darvocet/ propoxyphene multidistrict litigation cases, finding that the plaintiffs either failed to properly plead their claims... Read More

Tags: drugs , and Propoxyphene Products Liability Litigation , preemption , Sixth Circuit U.S. Court of Appeals , Darvon , In re: Darvocet , Inc. v. Bartlett , drug design defect preemption , Darvocet , Yanise Germain , Xanodyne Pharmaceuticals Inc. , Litigation , Inc. , multidistrict litigation , propoxyphene , generic drug manufacturers , Eli Lilly and Co. , usa , MDL , torts , Mutual Pharmacy Co. , et al. v. Teva Pharmaceuticals

Watchdog Group Makes 2nd Push To Ban Diet Pill
Posted on 15 Apr 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) For the second time in five years, public health advocates are calling on the Food and Drug Administration to ban a fat-blocking drug sold over-the counter and via prescription, pointing to new reports of kidney stones and pancreatic... Read More

Tags: Pondimin , Wyeth , obesity , Food and Drug Administration , Darvon , Public Citizen , Alli , diet drugs , diet pill , Meridia , FDA , Orlistat , fen-phen , fenfluramine , Redux , Litigation , GlaxoSmithKline , Roche , Xenical